Female Sexual Deside Dysfunction
Start Date 2015-01-12
End Date 2017-07-01
Eligibility Requirements
Eligibility
Gender
Gender
Female
Age Range
Age Range
18 - 25 years
26 - 30 years
31 - 45 years
Vetaran Status
Vetaran Status
Service Range
Service Range
Deployment Status
Deployment Status
Military Affiliation
Military Affiliation
Short Description
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
Location Info
Conducted in
Oakland , California
Privacy of the Participants
Does this study require the individual's medical records? - Yes
Does the sponsor require the name of study participants to be provided? - Yes
Is this study required to provide individual results to the sponsor? - Yes
Is this study anonymous in the sense that patient identity is completely anonymized? - Yes
Contact Details
Cheri Savercool 877-602-5777 [email protected]
Research Topics
Family Studies
Self-Help
Mental Health
More Info
Has this study and the posting of this study on AllyResearch.org been IRB approved - Yes
Are healthy subjects accepted? - No
Does this study utilize any drug treatments? - Yes
Are there financial incentives to participate? - Yes
Financial Incentive for this study :
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
University IRB
N/A
Study ID #
NCT02338960
Lead Researcher
Ira, Glick
Sponsored By
Palatin